Dr. Huntington Potter and his team were recently awarded a total of $1 million over two years from the Alzheimer’s Association to advance the Leukine® trial to further assess the potential of slowing or even stopping the progression of Alzheimer’s disease. Part of the Alzheimer’s Association’s Part the Cloud Challenge on Neuroinflammation initiative, this grant was awarded to speed investigation of new and innovative approaches to Alzheimer’s disease treatment, including those that target neuroinflammation. CU Anschutz was one of four award-winners – along with the Bellvitge Biomedical Research Institute in Spain; the University of California, Davis; and Longeveron, LLC, in Florida. After the initial two-year funding period, the research project showing the most viable translation into advanced clinical trials will receive an additional award of up to $3 million to further therapy development.

Click here to read the rest of the story at UCDenver.edu